
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2595702/publications.pdf Version: 2024-02-01



SETH L RALIED

#	Article	IF	CITATIONS
1	Association Between Colistin Dose and Microbiologic Outcomes in Patients With Multidrug-Resistant Gram-Negative Bacteremia. Clinical Infectious Diseases, 2013, 56, 398-404.	2.9	91
2	Predictors of response to fixed-dose vasopressin in adult patients with septic shock. Annals of Intensive Care, 2018, 8, 35.	2.2	71
3	Pharmacokinetics and Pharmacodynamics of Piperacillin-Tazobactam in 42 Patients Treated with Concomitant CRRT. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 452-457.	2.2	70
4	Systematic Review and Meta-Analysis of Procalcitonin-Guidance Versus Usual Care for Antimicrobial Management in Critically III Patients: Focus on Subgroups Based on Antibiotic Initiation, Cessation, or Mixed Strategies*. Critical Care Medicine, 2018, 46, 684-690.	0.4	66
5	Association of Catecholamine Dose, Lactate, and Shock Duration at Vasopressin Initiation With Mortality in Patients With Septic Shock*. Critical Care Medicine, 2022, 50, 614-623.	0.4	56
6	What is the role of supplementation with ascorbic acid, zinc, vitamin D, or <i>N</i> -acetylcysteine for prevention or treatment of COVID-19?. Cleveland Clinic Journal of Medicine, 2020, , .	0.6	51
7	The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness. Critical Care Medicine, 2021, 49, 598-622.	0.4	49
8	Lactic acidosis: Clinical implications and management strategies. Cleveland Clinic Journal of Medicine, 2015, 82, 615-624.	0.6	43
9	Association Between Volume of Fluid Resuscitation and Intubation in High-Risk Patients With Sepsis, Heart Failure, End-Stage Renal Disease, and Cirrhosis. Chest, 2020, 157, 286-292.	0.4	38
10	A pulmonary embolism response team (PERT) approach: initial experience from the Cleveland Clinic. Journal of Thrombosis and Thrombolysis, 2018, 46, 186-192.	1.0	36
11	Noninferiority of Inhaled Epoprostenol to Inhaled Nitric Oxide for the Treatment of ARDS. Annals of Pharmacotherapy, 2015, 49, 1105-1112.	0.9	34
12	Influence of Colistin Dose on Global Cure in Patients with Bacteremia Due to Carbapenem-Resistant Gram-Negative Bacilli. Antimicrobial Agents and Chemotherapy, 2016, 60, 431-436.	1.4	33
13	Therapeutic Drug Monitoring of Piperacillin-Tazobactam Using Spent Dialysate Effluent in Patients Receiving Continuous Venovenous Hemodialysis. Antimicrobial Agents and Chemotherapy, 2011, 55, 557-560.	1.4	31
14	Impact of Combination Antimicrobial Therapy on Mortality Risk for Critically Ill Patients with Carbapenem-Resistant Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 3748-3753.	1.4	30
15	Discontinuation of vasopressin before norepinephrine increases the incidence of hypotension in patients recovering from septic shock: A retrospective cohort study. Journal of Critical Care, 2010, 25, 362.e7-362.e11.	1.0	29
16	Effect of corticosteroids on arginine vasopressin–containing vasopressor therapy for septic shock: a case control study. Journal of Critical Care, 2008, 23, 500-506.	1.0	28
17	1401: THE GOLDILOCKS ZONE: VASOPRESSIN RESPONSE IS DEPENDENT ON ADMISSION LACTATE AND TIMING OF INITIATION. Critical Care Medicine, 2018, 46, 684-684.	0.4	28
18	Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection. International Journal of Antimicrobial Agents, 2013, 42, 553-558.	1.1	27

#	Article	IF	CITATIONS
19	Hypotension Risk Based on Vasoactive Agent Discontinuation Order in Patients in the Recovery Phase of Septic Shock. Pharmacotherapy, 2018, 38, 319-326.	1.2	24
20	Effect of Body Mass Index on Bleeding Frequency and Activated Partial Thromboplastin Time in Weight-Based Dosing of Unfractionated Heparin: A Retrospective Cohort Study. Mayo Clinic Proceedings, 2009, 84, 1073-1078.	1.4	23
21	Arginine Vasopressin for the Treatment of Septic Shock in Adults. Pharmacotherapy, 2010, 30, 1057-1071.	1.2	23
22	Risk Factors Associated with Bleeding After Alteplase Administration for Pulmonary Embolism: A Caseâ€Control Study. Pharmacotherapy, 2014, 34, 818-825.	1.2	22
23	Pharmacokinetics and Pharmacodynamics of Imipenem and Meropenem in Critically III Patients Treated With Continuous Venovenous Hemodialysis. American Journal of Kidney Diseases, 2014, 63, 170-171.	2.1	21
24	Effects of Norepinephrine and Vasopressin Discontinuation Order in the Recovery Phase of Septic Shock: A Systematic Review and Individual Patient Data Metaâ€Analysis. Pharmacotherapy, 2019, 39, 544-552.	1.2	19
25	Vasoactive Agent Use in Septic Shock: Beyond Firstâ€Line Recommendations. Pharmacotherapy, 2019, 39, 369-381.	1.2	19
26	Safe Use of Vasopressin and Angiotensin <scp>II</scp> for Patients with Circulatory Shock. Pharmacotherapy, 2018, 38, 851-861.	1.2	18
27	Lack of an Effect of Body Mass on the Hemodynamic Response to Arginine Vasopressin During Septic Shock. Pharmacotherapy, 2008, 28, 591-599.	1.2	17
28	Perceived safety and efficacy of neuromuscular blockers for acute respiratory distress syndrome among medical intensive care unit practitioners: A multicenter survey. Journal of Critical Care, 2017, 38, 278-283.	1.0	17
29	Vasopressin Plasma Concentrations Are Not Associated with Hemodynamic Response to Exogenous Vasopressin for Septic Shock. Pharmacotherapy, 2020, 40, 33-39.	1.2	15
30	Lack of cross-reactivity to meropenem in a patient with an allergy to imipenem-cilastatin. Journal of Allergy and Clinical Immunology, 2004, 113, 173-175.	1.5	14
31	Effectiveness of venous thromboembolism prophylaxis in patients with liver disease. World Journal of Hepatology, 2019, 11, 379-390.	0.8	14
32	Intensive Care Nurses' Knowledge About Use of Neuromuscular Blocking Agents in Patients With Respiratory Failure. American Journal of Critical Care, 2015, 24, 431-439.	0.8	13
33	Antimicrobial Monotherapy versus Combination Therapy for the Treatment of Complicated Intra-Abdominal Infections. Pharmacotherapy, 2016, 36, 1138-1144.	1.2	13
34	Effect of Phenylephrine Push Before Continuous Infusion Norepinephrine in Patients With Septic Shock. Chest, 2021, 159, 1875-1883.	0.4	13
35	Association Between Vasopressin Rebranding and Utilization in Patients With Septic Shock*. Critical Care Medicine, 2022, 50, 644-654.	0.4	13
36	Cost-effectiveness of second-line vasopressors for the treatment of septic shock. Journal of Critical Care, 2020, 55, 48-55.	1.0	12

#	Article	IF	CITATIONS
37	Liposomal bupivacaine versus continuous infusion bupivacaine via an elastomeric pump for the treatment of postoperative pain. American Journal of Health-System Pharmacy, 2015, 72, S127-S132.	0.5	11
38	Procalcitonin-based algorithms to initiate or stop antibiotic therapy in critically ill patients: Is it time to rethink our strategy?. International Journal of Antimicrobial Agents, 2016, 47, 20-27.	1.1	11
39	Bispectral Index for Titrating Sedation in ARDS Patients During Neuromuscular Blockade. American Journal of Critical Care, 2019, 28, 377-384.	0.8	11
40	Frequency, Timing, and Types of Medication Ordering Errors Made by Residents in the Electronic Medical Records Era. Southern Medical Journal, 2019, 112, 25-31.	0.3	11
41	Perceptions regarding vasopressin use and practices in septic shock, and cost containment strategies. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 257-267.	0.5	10
42	Comparison of Oral Vancomycin Capsule and Solution for Treatment of Initial Episode of Severe <i>Clostridium difficile</i> Infection. Journal of Pharmacy Practice, 2015, 28, 183-188.	0.5	9
43	Mortality, Morbidity, and Costs After Implementation of a Vasopressin Guideline in Medical Intensive Care Patients With Septic Shock: An Interrupted Time Series Analysis. Annals of Pharmacotherapy, 2020, 54, 314-321.	0.9	9
44	Association of Arterial pH With Hemodynamic Response to Vasopressin in Patients With Septic Shock: An Observational Cohort Study. , 2022, 4, e0634.		9
45	Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. Shock, 2021, 55, 210-214.	1.0	8
46	Compliance with Procalcitonin Algorithm Antibiotic Recommendations for Patients in Medical Intensive Care Unit. Pharmacotherapy, 2017, 37, 177-186.	1.2	7
47	Renal Transplant Acute Rejection with Lower Mycophenolate Mofetil Dosing and Proton Pump Inhibitors or Histamineâ€2 Receptor Antagonists. Pharmacotherapy, 2017, 37, 1507-1515.	1.2	7
48	Body Mass's Impact on Response to Fixed-Dose Vasopressin in Patients With Septic Shock. Shock, 2018, 50, 388-394.	1.0	7
49	Effectiveness, safety, and Economic Comparison of Two Inhaled Epoprostentol Products (Flolan and) Tj ETQq1 1	0.784314	4 rgBT /Over
50	Predictors of septic shock in patients with methicillin-resistant Staphylococcus aureus bacteremia. International Journal of Infectious Diseases, 2012, 16, e453-e456.	1.5	6
51	Educational Targets to Reduce Medication Errors by General Surgery Residents. Journal of Surgical Education, 2019, 76, 1612-1621.	1.2	6
52	Effectiveness, Safety, and Economic Comparison of Inhaled Epoprostenol Brands, Flolan and Veletri, in Acute Respiratory Distress Syndrome. Annals of Pharmacotherapy, 2020, 54, 434-441.	0.9	6
53	Corticosteroids for Septic Shock: Another Chapter in the Saga. Hospital Pharmacy, 2020, 55, 135-142.	0.4	5
54	Hemodynamic Response to Vasopressin Dosage of 0.03 Units/Min vs. 0.04 Units/Min in Patients With Septic Shock. Journal of Intensive Care Medicine, 2022, 37, 92-99.	1.3	5

#	Article	IF	CITATIONS
55	Association Between Compliance With the Sepsis Quality Measure (SEP-1) and Hospital Readmission. Chest, 2020, 158, 608-611.	0.4	5
56	Ethanol Exposure Attenuates Immune Response in Sepsis via Sirtuin 2 Expression. Alcoholism: Clinical and Experimental Research, 2021, 45, 338-350.	1.4	5
57	Evaluation of an updated insulin infusion protocol at a large academic medical center. American Journal of Health-System Pharmacy, 2016, 73, S88-S93.	0.5	4
58	Development of the Critical Care Pharmacotherapy Trials Network. American Journal of Health-System Pharmacy, 2017, 74, 287-293.	0.5	4
59	Optimal norepinephrine-equivalent dose to initiate epinephrine in patients with septic shock. Journal of Critical Care, 2019, 53, 69-74.	1.0	4
60	Continuous Medical Education Changes Practice: One Year After SMART and SALT-ED. , 2019, 1, e0017.		4
61	Inter-rater Agreement for Abstraction of the Early Management Bundle, Severe Sepsis/Septic Shock (SEP-1)ÂQuality Measure in a Multi-Hospital Health System. Joint Commission Journal on Quality and Patient Safety, 2019, 45, 108-111.	0.4	4
62	Did the beneficial renal outcomes with vasopressin VANISH?. Annals of Translational Medicine, 2016, 4, S67-S67.	0.7	4
63	Corticosteroids in acute lung injury and acute respiratory distress syndrome. Critical Care Medicine, 2009, 37, 2680-2681.	0.4	3
64	Initial Care for Patients with Severe Sepsis and Septic Shock: The Next ICU Quality Measure. Hospital Pharmacy, 2016, 51, 19-25.	0.4	3
65	Association of Methylene Blue Dosing with Hemodynamic Response for the Treatment of Vasoplegia. Journal of Cardiothoracic and Vascular Anesthesia, 2022, , .	0.6	3
66	Detectability of Vasopressin in Continuous Venovenous Hemodialysis Effluent of Patients with Vasodilatory Shock Treated with Exogenous Arginine Vasopressin. Pharmacotherapy, 2011, 31, 857-862.	1.2	2
67	Compliance With Institutional Antimicrobial Dosing Guidelines in Patients Receiving Continuous Venovenous Hemodialysis. Journal of Pharmacy Practice, 2015, 28, 380-386.	0.5	2
68	Effectiveness and Safety of Twice Daily Versus Thrice Daily Subcutaneous Unfractionated Heparin for Venous Thromboembolism Prophylaxis at a Tertiary Medical Center. Journal of Pharmacy Practice, 2020, , 089719002096121.	0.5	2
69	Critical care essentials for pharmacy trainees and new clinical practitioners. American Journal of Health-System Pharmacy, 2021, 78, 1176-1183.	0.5	2
70	1398: EFFECT OF BASELINE PH ON VASOPRESSIN RESPONSE IN PATIENTS WITH SEPTIC SHOCK. Critical Care Medicine, 2018, 46, 683-683.	0.4	1
71	Inpatient Initiation of Oral Treprostinil in an Academic Medical System. Cardiovascular Drugs and Therapy, 2020, 34, 547-553.	1.3	1
72	Institutional care paths: Development, implementation, and evaluation. American Journal of Health-System Pharmacy, 2017, 74, 1486-1493.	0.5	0

#	Article	IF	CITATIONS
73	Response. Chest, 2021, 159, 878-879.	0.4	Ο
74	Author's Response: Abrupt Discontinuation Versus Down-Titration of Vasopressin in Patients Recovering from Septic Shock. Shock, 2021, 56, 870.	1.0	0
75	EFFECTS OF BODY WEIGHT ON HEMODYNAMIC RESPONSE TO ARGININE VASOPRESSIN DURING SEPTIC SHOCK Critical Care Medicine, 2006, 34, A106.	0.4	Ο
76	EFFECT OF CORTICOSTEROIDS ON TIME TO WITHDRAWAL OF ARGININE VASOPRESSIN-CONTAINING VASOPRESSOR THERAPY IN SEPTIC SHOCK Critical Care Medicine, 2006, 34, A106.	0.4	0
77	Continuation or Discontinuation of Statin Therapy Did Not Influence Patient Outcomes after the Development of Acute Respiratory Distress Syndrome. ISRN Critical Care, 2013, 2013, 1-8.	0.0	0